Company / Gross Profit per Share
NeoGenomics Laboratories, Inc. Gross Profit per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$2.45
FY2025
5-year range
$1.51 / $2.45
FY2021-FY2025
Trend
+7.1%
vs FY2024
Sector context
#88 of 99
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s gross profit per share of $2.45 is lower than 89% of companies in the Health Care sector (FY2025). Gross Profit per Share has increased for 3 consecutive years, from $1.51 in FY2022 to $2.45 in FY2025.
Based on SEC 10-K filings.
2.45 in FY2025 with a 5-year CAGR of +8.1%.
Improved from $1.95 to $2.45 over the past 2 years.
Health Care sector context is included.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +17.5%
- 5-Year CAGR
- +8.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 99This company $2.45 Sector average $13.98
▼
-82.4% below sector average
Key checks
Key Insights
- NeoGenomics Laboratories, Inc.'s gross profit per share has grown for 3 consecutive years.
- In FY2025, gross profit per share increased 7.1% year-over-year.
- Ranks #88 out of 99 companies in the Health Care sector.
- Lowest gross profit per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.45 | +7.1% |
| FY2024 | $2.29 | +17.5% |
| FY2023 | $1.95 | +28.8% |
| FY2022 | $1.51 | -3.0% |
| FY2021 | $1.56 | -6.2% |
| FY2020 | $1.66 | -12.5% |
| FY2019 | $1.90 | +36.7% |
| FY2018 | $1.39 | +7.1% |
| FY2017 | $1.30 | +0.3% |
| FY2016 | $1.29 | +78.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026